Patient background and laboratory variables associated with the efficacy of nivolumab after chemoradiotherapy in esophageal squamous cell carcinoma

Sekino,Nobufumi; Toyozumi,Takeshi; Murakami,Kentaro; Uesato,Masaya; Nakano,Akira; Shiraishi,Tadashi; Hayano,Koichi; Matsumoto,Yasunori; Kurata,Yoshihiro; Otsuka,Ryota; Hirano,Sho; Hayashi,Hideki; Matsubara,Hisahiro

doi:10.3892/mco.2025.2885

Patient background and laboratory variables associated with the efficacy of nivolumab after chemoradiotherapy in esophageal squamous cell carcinoma

Authors:
- Nobufumi Sekino
- Takeshi Toyozumi
- Kentaro Murakami
- Masaya Uesato
- Akira Nakano
- Tadashi Shiraishi
- Koichi Hayano
- Yasunori Matsumoto
- Yoshihiro Kurata
- Ryota Otsuka
- Sho Hirano
- Hideki Hayashi
- Hisahiro Matsubara
View Affiliations

Affiliations: Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan
Published online on: August 7, 2025 https://doi.org/10.3892/mco.2025.2885
Article Number: 90
Copyright: © Sekino et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is refractory to multidisciplinary treatment. Immunotherapy targeting programmed cell death protein 1 has shown promise in recent years; however, predicting its therapeutic efficacy remains difficult. The present study aimed to identify the factors associated with treatment response in patients receiving nivolumab after radical chemoradiotherapy for ESCC and to predict treatment efficacy based on these factors. A total of 22 patients were classified into partial response (PR) + stable disease (SD) and progressive disease (PD) groups based on their response to nivolumab. Factors associated with the treatment response were analyzed, including clinical stage, patient background and pre‑treatment blood test results. Among the 22 patients, nine and 13 were classified into the PR + SD and PD groups, respectively. Notably, treatment efficacy had a significant impact on prognosis. Variables such as height, weight, body mass index, white blood cell count, basophil fraction, platelet count, albumin, creatinine and C‑reactive protein were also evaluated. Cut‑off values were determined using the Youden index for body weight (53.5 kg), white blood cells (5,000/mm3), basophils (0.6%), platelets (145x104/mm3), albumin (3.9 m g/dl) and C‑reactive protein (0.10 mg/dl). The number of favorable variables was calculated for each patient based on these cut‑off values. Nine patients in the PR + SD group had three or more favorable variables, whereas 13 patients in the PD group had two or fewer. In conclusion, although the current study had a limited sample size, the six identified variables appear promising for predicting the efficacy of immune checkpoint inhibitors.

View Figures

View References

1	Takeuchi H, Miyata H, Gotoh M, Kitagawa Y, Baba H, Kimura W, Tomita N, Nakagoe T, Shimada M, Sugihara K and Mori M: A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide Web-based database. Ann Surg. 260:259–266. 2014.PubMed/NCBI View Article : Google Scholar
2	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.PubMed/NCBI View Article : Google Scholar
3	Tachimori Y, Ozawa S, Numasaki H, Fujishiro M, Matsubara H, Oyama T, Shinoda M, Toh Y, Udagawa H and Uno T: Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive registry of esophageal cancer in Japan, 2009. Esophagus. 13:110–137. 2016.PubMed/NCBI View Article : Google Scholar
4	Wang R, Liu S, Chen B and Xi M: Recent advances in combination of immunotherapy and chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancers (Basel). 14(5168)2022.PubMed/NCBI View Article : Google Scholar
5	Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, et al: Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20:1506–1517. 2019.PubMed/NCBI View Article : Google Scholar
6	Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, et al: Nivolumab combination therapy in advanced esophageal Squamous-Cell carcinoma. N Engl J Med. 386:449–462. 2022.PubMed/NCBI View Article : Google Scholar
7	Kato K, Kojima T, Hara H, Tsuji A, Yasui H, Muro K, Satoh T, Ogata T, Ishihara R, Goto M, et al: First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study. Esophagus. 21:306–318. 2024.PubMed/NCBI View Article : Google Scholar
8	Xue Y, Zhou X, Xue L, Zhou R and Luo J: The role of pretreatment prognostic nutritional index in esophageal cancer: A meta-analysis. J Cell Physiol. 234:19655–19662. 2019.PubMed/NCBI View Article : Google Scholar
9	Zhang H, Shang X, Ren P, Gong L, Ahmed A, Ma Z, Ma R, Wu X, Xiao X, Jiang H, et al: The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. J Cell Physiol. 234:1794–802. 2019.PubMed/NCBI View Article : Google Scholar
10	Wang Y, Chen L, Wu Y, Li P and Che G: The prognostic value of modified Glasgow prognostic score in patients with esophageal squamous cell cancer: A Meta-analysis. Nutr Cancer. 72:1146–1154. 2020.PubMed/NCBI View Article : Google Scholar
11	Sakai M, Sohda M, Saito H, Ubukata Y, Nakazawa N, Kuriyama K, Hara K, Sano A, Ogata K, Yokobori T, et al: Comparative analysis of immunoinflammatory and nutritional measures in surgically resected esophageal cancer: A Single-center retrospective study. In Vivo. 34:881–887. 2020.PubMed/NCBI View Article : Google Scholar
12	Ignacio de Ulíbarri J, González-Madroño A, de Villar NG, González P, González B, Mancha A, Rodríguez F and Fernández G: CONUT: A tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 20:38–45. 2005.PubMed/NCBI
13	Takagi K, Buettner S, Ijzermans JNM and Wijnhoven BPL: Systematic review on the controlling nutritional status (CONUT) score in patients undergoing esophagectomy for esophageal cancer. Anticancer Res. 40:5343–5349. 2020.PubMed/NCBI View Article : Google Scholar
14	Makino T, Nakai S, Momose K, Yamashita K, Tanaka K, Miyata H, Yamamoto S, Motoori M, Kimura Y, Ushimaru Y, et al: Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: Real-world clinical data from a large Multi-institutional cohort. Esophagus. 21:319–327. 2024.PubMed/NCBI View Article : Google Scholar
15	Kosumi K, Baba Y, Hara Y, Wang H, Nomoto D, Toihata T, Ohuchi M, Harada K, Eto K, Ogawa K, et al: Body composition and clinical outcomes in esophageal cancer patients treated with immune checkpoint inhibitors. Ann Surg Oncol. 31:3839–3849. 2024.PubMed/NCBI View Article : Google Scholar
16	Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al: Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: Part 1. Esophagus. 16:1–24. 2019.PubMed/NCBI View Article : Google Scholar
17	Hino C, Lee EW and Yang GY: Harnessing the abscopal effect for gastrointestinal malignancies in the era of immunotherapy. J Gastrointest Oncol. 14:1613–1625. 2023.PubMed/NCBI View Article : Google Scholar
18	Lee JH, Kang D, Ahn JS, Guallar E, Cho J and Lee HY: Obesity paradox in patients with Non-small cell lung cancer undergoing immune checkpoint inhibitor therapy. J Cachexia Sarcopenia Muscle. 14:2898–2907. 2023.PubMed/NCBI View Article : Google Scholar
19	Tanaka T, Narazaki M and Kishimoto T: IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 6(a016295)2014.PubMed/NCBI View Article : Google Scholar
20	Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S and Ochiai T: Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 83:248–252. 2003.PubMed/NCBI View Article : Google Scholar
21	Sektioglu IM, Carretero R, Bulbuc N, Bald T, Tüting T, Rudensky AY and Hämmerling GJ: Basophils promote tumor rejection via chemotaxis and infiltration of CD8+ T cells. Cancer Res. 77:291–302. 2017.PubMed/NCBI View Article : Google Scholar
22	Kang TG, Park HJ, Moon J, Lee JH and Ha SJ: Enriching CCL3 in the tumor microenvironment facilitates T cell Responses and improves the efficacy of Anti-PD-1 therapy. Immune Netw. 21(e23)2021.PubMed/NCBI View Article : Google Scholar
23	Wu C, Qiu Y, Zhang R, Li X, Liang H, Wang M, Li F, Zhu M, Ye G, Liu H, et al: Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer. J Transl Med. 20(386)2022.PubMed/NCBI View Article : Google Scholar
24	Rosner S, Kwong E, Shoushtari AN, Friedman CF, Betof AS, Brady MS, Coit DG, Callahan MK, Wolchok JD, Chapman PB, et al: Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med. 7:690–697. 2018.PubMed/NCBI View Article : Google Scholar
25	Krizova L, Benesova I, Zemanova P, Spacek J, Strizova Z, Humlova Z, Mikulova V, Petruzelka L and Vocka M: Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors. J Cancer Res Clin Oncol. 150(99)2024.PubMed/NCBI View Article : Google Scholar
26	LaMarche NM, Hegde S, Park MD, Maier BB, Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin C, et al: An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature. 625:166–1674. 2024.PubMed/NCBI View Article : Google Scholar
27	Muller M, Best MG, van der Noort V, Hiltermann TJN, Niemeijer AN, Post E, Sol N, In 't Veld SGJG, Nogarede T, Visser L, et al: Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with Non-small cell lung cancer. Tumour Biol. 46 (Suppl):S327–S340. 2024.PubMed/NCBI View Article : Google Scholar
28	Inoue H, Shiozaki A, Fujiwara H, Konishi H, Kiuchi J, Ohashi T, Shimizu H, Arita T, Yamamoto Y, Morimura R, et al: Absolute lymphocyte count and C-reactive protein-albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy. Oncol Lett. 24(257)2022.PubMed/NCBI View Article : Google Scholar
29	Zhang H, Lin J, Huang Y and Chen Y: The systemic Immune-inflammation index as an independent predictor of survival in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant radiotherapy. J Inflamm Res. 17:4575–4586. 2024.PubMed/NCBI View Article : Google Scholar
30	Counsilman CE, Jol-van der Zijde CM, Stevens J, Cransberg K, Bredius RG and Sukhai RN: Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatr Nephrol. 30:1367–1370. 2015.PubMed/NCBI View Article : Google Scholar